key: cord-0783159-wc41epnv authors: Hörner, Cindy; Schürmann, Christoph; Auste, Arne; Ebenig, Aileen; Muraleedharan, Samada; Herrmann, Maike; Schnierle, Barbara; Mühlebach, Michael D. title: A Highly Immunogenic Measles Virus-based Th1-biased COVID-19 Vaccine date: 2020-07-11 journal: bioRxiv DOI: 10.1101/2020.07.11.198291 sha: e38478c1bcb3cfb1fb5db3f26b2a7246984338c9 doc_id: 783159 cord_uid: wc41epnv The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread world-wide with millions of cases and hundreds of thousands of deaths to date. The gravity of the situation mandates accelerated efforts to identify safe and effective vaccines. Here, we generated measles virus (MeV)-based vaccine candidates expressing the SARS-CoV-2 spike glycoprotein (S). Insertion of the full-length S protein gene in two different MeV genomic positions resulted in modulated S protein expression. The variant with lower S protein expression levels was genetically stable and induced high levels of effective Th1-biased antibody and T cell responses in mice after two immunizations. In addition to neutralizing IgG antibody responses in a protective range, multifunctional CD8+ and CD4+ T cell responses with S protein-specific killing activity were detected. These results are highly encouraging and support further development of MeV-based COVID-19 vaccines. Author Contributions CH performed research, analyzed data, and wrote the paper; CS performed research and analyzed data; AA performed research and analyzed data; AE performed research and analyzed data; SM performed research, analyzed data, and wrote the paper; MH developed the bioinformatics pipeline and analyzed data; BS contributed new reagents and concepts; MDM designed and supervised research, analyzed data and wrote the paper; all authors read, corrected and approved the final manuscript. Significance Statement The COVID-19 pandemic has caused hundreds of thousands of deaths, yet. Therefore, effective vaccine concepts are urgently needed. In search for such a concept, we have analysed a measles virus-based vaccine candidate targeting SARS-CoV-2. Using this well known, safe vaccine backbone, we demonstrate here induction of functional immune responses in both arms of adaptive immunity with the desired immune bias. Therefore, occurrence of immunopathologies such as antibody-dependent enhancement or enhanced respiratory disease is rather unlikely. Moreover, the candidate still induces immunity against the measles, recognized as a looming second menace, when countries are entrapped to stop routine vaccination campaigns in the face of COVID-19. Thus, a bivalent measles-based COVID-19 vaccine could be the solution for two significant public health threats. To investigate if this increased fusion activity is due to SARS-CoV-2 S protein-mediated cell-to-cell ELISpot assays using splenocytes of vaccinated animals in co-culture with DC2.4-SARS2-S cells 181 revealed more than 1,400 IFN- secreting cells per 110 6 splenocytes after immunization with 182 MeVvac2-SARS2-S(H), respectively (Fig. 3) . In contrast, co-culture with splenocytes of control mice 183 resulted in a background response of less than 50 IFN- producing cells per 110 6 splenocytes. As To demonstrate the effector ability of induced cytotoxic T lymphocytes (CTLs), a killing assay was 259 performed to directly analyze antigen-specific cytotoxicity (Fig. 6) . Splenocytes of immunized mice 260 isolated 21 days post boost vaccination were co-cultured with DC2.4-SARS2-S or parental DC2.4 261 cells for 6 days to re-stimulate antigen-specific T cells. When these re-stimulated T cells were co-9 incubated with a defined mixture of EL-4green-SARS2-S target and EL-4red control cells (ratio 263 approximately 1:1), only T cells from MeVvac2-SARS2-S(H) vaccinated mice significantly shifted the 264 ratio of live SARS-CoV-2 S protein-expressing target cells to control cells in a dose-dependent 265 manner (Fig. 6B ). This antigen-dependent killing was also dependent on re-stimulation with DC2.4-266 SARS2-S cells, since unstimulated T cells did not significantly shift the ratios of target to non-target 267 cells (Fig. 6A ). These results indicate that CTLs isolated from MeVvac2-SARS2-S(H)-vaccinated mice are capable This observation is in accordance with the stability of anti-measles immunity (16) also after pediatric 353 vaccination (17) and might be a specific advantage of the measles vaccine platform technology. Also extended passaging of the vaccine candidate did not result in changes of the vaccine as 355 revealed by sequencing of the virus after 10 passages starting with a low MOI. This genetic stability 356 indicates that the slight impairment seen in multi-step growth curves when compared to a vaccine-357 strain MeV is not critical for the vaccine´s amplification and therefore crucial for product safety. In 358 accordance with its genetic stability, the minor enhancement of fusion activity can also be regarded Virus neutralizing titers (VNT) were quantified as described previously (7) . Towards this, sera were A new coronavirus associated with human respiratory disease in China Early Transmission Dynamics in Wuhan, China, of 725 Novel Coronavirus-Infected Pneumonia Substantial undocumented 728 infection facilitates the rapid dissemination of novel coronavirus Vaccine platform recombinant measles virus Protection from SARS coronavirus conferred by live measles vaccine expressing the spike 734 glycoprotein Induction of neutralising antibodies and cellular 737 immune responses against SARS coronavirus by recombinant measles viruses A Highly Immunogenic and Protective Middle Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine 744 Live-attenuated 746 bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome 747 coronavirus induce robust and multifunctional T cell responses against both viruses in an 748 appropriate mouse model A single amino acid substitution in the measles virus F₂ protein 751 reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains Measles Virus Spread and Pathogenesis in Genetically Modified Mice Towards an understanding of the adjuvant action of 756 aluminium Advances in aluminum hydroxide-based adjuvant research and its 758 mechanism Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human 762 Angiotensin-Converting Enzyme 2 hCD46 receptor is 764 not required for measles vaccine Schwarz strain replication in vivo: Type-I IFN is the species 765 barrier in mice Interferons Potently Enhance Humoral Immunity and Can Promote Isotype Switching by 768 Duration of Humoral Immunity to Common Viral and 770 Vaccine Antigens Long-term immunogenicity of measles, 772 mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up Remission of disseminated cancer after systemic oncolytic virotherapy Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. 780 Current cancer drug targets Phase I trial of systemic administration of Edmonston strain of measles virus 784 genetically engineered to express the sodium iodide symporter in patients with recurrent or 785 refractory multiple myeloma Understanding the causes and consequences of 787 measles virus persistence Immunogenicity, safety, and tolerability of a recombinant 790 measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, 791 active-comparator, first-in-man trial Immunogenicity, Safety, and Tolerability of 794 the Measles-Vectored Chikungunya Virus Vaccine MV-CHIK: A Double-Blind CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 799 Cryo-EM structure of the 2019-nCoV spike in the prefusion DNA vaccine protection against SARS-CoV-2 in rhesus macaques Severe Acute Respiratory Syndrome Coronavirus 2-Specific 816 Antibody Responses in Coronavirus Disease Patients The bright and the dark side of 819 human antibody responses to flaviviruses: lessons for vaccine design Anti-spike IgG causes severe acute lung injury by skewing macrophage responses 824 during acute SARS-CoV infection Human immunology of measles virus infection The pathogenicity of SARS-CoV-2 in hACE2 832 transgenic mice Pathogenesis and 835 transmission of SARS-CoV-2 in golden hamsters Simulation of the 840 clinical and pathological manifestations of Coronavirus Disease Syrian hamster model: implications for disease pathogenesis and transmissibility Cloned dendritic cells can present exogenous 843 antigens on both MHC class I and class II molecules DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and 848 enhanced safety. Molecular therapy : the journal of the American Society of Gene Therapy 21 Mutant 851 torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia 852 cells Multiply attenuated lentiviral vector 855 achieves efficient gene delivery in vivo DARPins: an efficient targeting domain for lentiviral vectors RNA polymerase II-controlled expression of antigenomic 860 RNA enhances the rescue efficacies of two different members of the Mononegavirales 861 independently of the site of viral genome replication Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche A 865 vectored measles virus induces hepatitis B surface antigen antibodies while protecting 866 macaques against measles virus challenge fastp: an ultra-fast all-in-one FASTQ preprocessor Fast and accurate short read alignment with Burrows-Wheeler transform The Sequence Alignment/Map format and SAMtools BEDTools: a flexible suite of utilities for comparing genomic features The Genome Analysis Toolkit: a MapReduce 878 framework for analyzing next-generation DNA sequencing data LoFreq: a sequence-quality aware, ultra-sensitive variant caller 882 for uncovering cell-population heterogeneity from high-throughput sequencing datasets Targeted cell entry of lentiviral vectors. Molecular therapy : the journal of the 886 Determination of lymphocyte division by flow cytometry